Predictive Value of Serum Calprotectin (S100A8/A9) for Clinical Response After Starting or Tapering Anti-TNF Treatment in Patients with Rheumatoid Arthritis

Overview

Journal RMD Open

Publisher BMJ Publishing Group

Specialty Rheumatology

Date 2018 Apr 17

PMID 29657832

Citations 15

Authors

Lieke Tweehuysen

Nathan den Broeder

Noortje van Herwaarden

Leo A B Joosten

Peter L van Lent

Thomas Vogl

Frank H J van den Hoogen

Rogier M Thurlings

Alfons A den Broeder

Affiliations

Soon will be listed here.

Abstract

Objectives: Calprotectin (S100A8/A9) has been correlated with disease activity in rheumatoid arthritis (RA). The aim of this study was to investigate the predictive value of serum calprotectin for clinical response after starting and tapering anti-tumour necrosis factor treatment in RA.

Methods: Serum samples and clinical outcomes were derived from two longitudinal RA studies.At baseline (starting or tapering of adalimumab or etanercept), calprotectin levels were determined by ELISA. In the Biologic Individual Optimised Treatment Outcome Prediction (BIO-TOP) study, treatment effect was assessed after 6 months using the European League Against Rheumatism (EULAR) response criteria. In the Dose Reduction Strategies of Subcutaneous TNF Inhibitors (DRESS) study, patients were classified at 18 months as being successfully dose reduced, discontinued or not able to reduce the dose. Area under the receiver operating characteristic curves (AUC) were generated to evaluate the predictive value of calprotectin and logistic prediction models were created to assess its added value.

Results: In the BIO-TOP study, calprotectin levels were higher in responders (n=50: 985 ng/mL (p25-p75: 558-1417)) compared with non-responders (n=75: 645 ng/mL (p25-p75: 415-973), p=0.04).AUC for predicting EULAR good response was 0.61 (95% CI 0.50 to 0.71). The prediction model with calprotectin (AUC 0.77, 95% CI 0.68 to 0.85) performed similarly to the baseline model (AUC 0.74, 95% CI 0.65 to 0.82, p=0.29). In the DRESS study, calprotectin levels were similar between the three groups (n=47; n=19; n=36) and calprotectin was not predictive for clinical response after tapering.

Conclusions: Serum calprotectin has some predictive value for clinical response after starting anti-TNF treatment, although it has no added value to other clinical factors. In patients with low disease activity, serum calprotectin is not predictive for clinical response after tapering anti-TNF treatment.

Trial Registration Number: NTR4647 (BIO-TOP study) and NTR3216 (DRESS study); Pre-results.

Citing Articles

Advances in S100 protein family for gynecological malignancies.

Wu S, Xu J Discov Oncol. 2025; 16(1):287.

PMID: 40057924 PMC: 11891126. DOI: 10.1007/s12672-025-02028-x.

Virtual Probing on the Influence of Ca and Zn Bound S100A8 and S100A9 Proteins Towards their Interaction Against Pattern Recognition Receptors Aggravating Rheumatoid Arthritis.

Paramasivam S, Murugesan J, Vedagiri H, Perumal S, Ekambaram S Cell Biochem Biophys. 2024; .

PMID: 39576489 DOI: 10.1007/s12013-024-01600-6.

The Role of Alarmins in the Pathogenesis of Rheumatoid Arthritis, Osteoarthritis, and Psoriasis.

Kielbowski K, Stanska W, Bakinowska E, Rusinski M, Pawlik A Curr Issues Mol Biol. 2024; 46(4):3640-3675.

PMID: 38666958 PMC: 11049642. DOI: 10.3390/cimb46040228.

CD64 as novel molecular imaging marker for the characterization of synovitis in rheumatoid arthritis.

Theeuwes W, Di Ceglie I, Dorst D, Blom A, Bos D, Vogl T Arthritis Res Ther. 2023; 25(1):158.

PMID: 37653557 PMC: 10468866. DOI: 10.1186/s13075-023-03147-y.

Serum calprotectin levels do not predict subsequent relapse in rheumatoid arthritis in remission: a post-hoc analysis of STRASS study.

Romand X, Clapasson M, Chuong M, Paclet M, Fautrel B, Baillet A RMD Open. 2023; 9(2).

PMID: 37364929 PMC: 10410922. DOI: 10.1136/rmdopen-2023-003198.

References

Garcia-Arias M, Pascual-Salcedo D, Ramiro S, Ueberschlag M, Jermann T, Cara C . Calprotectin in rheumatoid arthritis : association with disease activity in a cross-sectional and a longitudinal cohort. Mol Diagn Ther. 2013; 17(1):49-56. DOI: 10.1007/s40291-013-0016-9. View

van Herwaarden N, den Broeder A, Jacobs W, van der Maas A, Bijlsma J, van Vollenhoven R . Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev. 2014; (9):CD010455. DOI: 10.1002/14651858.CD010455.pub2. View

van Herwaarden N, van der Maas A, Minten M, van den Hoogen F, Kievit W, van Vollenhoven R . Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ. 2015; 350:h1389. PMC: 4391970. DOI: 10.1136/bmj.h1389. View

Patro P, Singh A, Misra R, Aggarwal A . Myeloid-related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate. J Rheumatol. 2016; 43(4):731-7. DOI: 10.3899/jrheum.150998. View

Hetland M, Christensen I, Tarp U, Dreyer L, Hansen A, Hansen I . Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide.... Arthritis Rheum. 2009; 62(1):22-32. DOI: 10.1002/art.27227. View

Nordal H, Brokstad K, Solheim M, Halse A, Kvien T, Hammer H . Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis. Arthritis Res Ther. 2017; 19(1):3. PMC: 5234113. DOI: 10.1186/s13075-016-1201-0. View

Cotoi O, Duner P, Ko N, Hedblad B, Nilsson J, Bjorkbacka H . Plasma S100A8/A9 correlates with blood neutrophil counts, traditional risk factors, and cardiovascular disease in middle-aged healthy individuals. Arterioscler Thromb Vasc Biol. 2013; 34(1):202-10. DOI: 10.1161/ATVBAHA.113.302432. View

Nair S, Bijlsma J, van der Werf J, van der Veen M, Linn-Rasker S, Vreugdenhil S . Do radiographic joint damage and disease activity influence functional disability through different mechanisms? Direct and indirect effects of disease activity in established rheumatoid arthritis. J Rheumatol. 2013; 40(9):1505-12. DOI: 10.3899/jrheum.121346. View

Obry A, Lequerre T, Hardouin J, Boyer O, Fardellone P, Philippe P . Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach. PLoS One. 2014; 9(12):e115800. PMC: 4278766. DOI: 10.1371/journal.pone.0115800. View

10.

Inciarte-Mundo J, Hernandez M, Ruiz-Esquide V, Cabrera-Villalba S, Ramirez J, Cuervo A . Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors. Arthritis Care Res (Hoboken). 2016; 68(7):899-906. DOI: 10.1002/acr.22795. View

11.

Welsing P, Landewe R, van Riel P, Boers M, van Gestel A, van der Linden S . The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum. 2004; 50(7):2082-93. DOI: 10.1002/art.20350. View

12.

Hammer H, Odegard S, Syversen S, Landewe R, van der Heijde D, Uhlig T . Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. Ann Rheum Dis. 2008; 69(1):150-4. DOI: 10.1136/ard.2008.103739. View

13.

Bae S, Lee Y . Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis. Postgrad Med. 2017; 129(5):531-537. DOI: 10.1080/00325481.2017.1319729. View

14.

Anink J, van Suijlekom-Smit L, Otten M, Prince F, van Rossum M, Dolman K . MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. Arthritis Res Ther. 2015; 17:200. PMC: 4528380. DOI: 10.1186/s13075-015-0723-1. View

15.

Nordal H, Brun J, Hordvik M, Eidsheim M, Jonsson R, Halse A . Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab. Scand J Rheumatol. 2016; 45(4):274-81. DOI: 10.3109/03009742.2015.1107128. View

16.

Cascao R, Rosario H, Souto-Carneiro M, Fonseca J . Neutrophils in rheumatoid arthritis: More than simple final effectors. Autoimmun Rev. 2010; 9(8):531-5. DOI: 10.1016/j.autrev.2009.12.013. View

17.

DeLong E, Delong D, Clarke-Pearson D . Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44(3):837-45. View

18.

Maksymowych W, FitzGerald O, Wells G, Gladman D, Landewe R, Ostergaard M . Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. J Rheumatol. 2009; 36(8):1792-9. DOI: 10.3899/jrheum090347. View

19.

Frosch M, Strey A, Vogl T, Wulffraat N, Kuis W, Sunderkotter C . Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000; 43(3):628-37. DOI: 10.1002/1529-0131(200003)43:3<628::AID-ANR20>3.0.CO;2-X. View

20.

Cuppen B, Welsing P, Sprengers J, Bijlsma J, Marijnissen A, van Laar J . Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. Rheumatology (Oxford). 2015; 55(5):826-39. DOI: 10.1093/rheumatology/kev421. View